FDA's Patrizia Cavazzoni to retire as CDER chief in 2nd senior official's departure in span of weeks
The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...
GlobalData on MSN9d
FDA CDER director Patrizia Cavazzoni announces resignationFollowing a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.
has confirmed that its director of the Centre for Drug Evaluation and Research (CDER), Patrizia Cavazzoni, has announced her resignation ahead of Donald Trump’s inauguration on 20 January.
The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...
The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...
Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.
The rate of warnings initiated by the FDA continues to rise in the pharma and medical device industries. Knowing how to best ...
MATTB provides assistance and training through outreach to industry. A: CDER's Division of Drug Information (DDI) serves as a focal point for public inquiries regarding human drug products.
The FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new small molecules, biologics and oligonucleotide therapeutics last year. The class of 2024 was a little smaller than that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback